Fig. 2

Network plot for primary outcomes and secondary outcomes. The lines between nodes represent direct comparisons in various trials, and each circle's size is proportional to the population involved in each specific treatment. The thickness of the lines is proportional to the number of trials connected to the network. DFN-02, sumatriptan nose spray 10 mg with a permeation enhancer; AVP-825, a drug-device combination of 22mg sumatriptan powder; MAP0004, a dihydroergotamine inhaler; ROX-828, ketorolac 31.5mg with 6% of lidocaine